Abstract
The use of oncolytic herpes simplex virus type 1 (HSV-1) is a promising strategy for cancer treatment. Accumulating evidence indicates that, aside from the extent of replication capability within the tumor, the efficacy of an oncolytic HSV-1 depends on the extent of induction of host antitumor immune responses. Ways to modify the host immune responses toward viral oncolysis include expression of immunostimulatory molecules using oncolytic HSV-1 as a vector and co-administration of reagents that modulate immune reactions. Viral propagation may be enhanced via temporary suppression of innate immune responses. Elucidation of the role of the host immune system in oncolytic HSV-1 therapy is the key to establishing the approach as a useful clinical means for cancer treatment.
Keywords: Herpes simplex virus type 1, oncolytic virus therapy, antitumor immunity, cancer immunotherapy, innate immunity
Current Cancer Drug Targets
Title: Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Volume: 7 Issue: 2
Author(s): Hiroshi Fukuhara and Tomoki Todo
Affiliation:
Keywords: Herpes simplex virus type 1, oncolytic virus therapy, antitumor immunity, cancer immunotherapy, innate immunity
Abstract: The use of oncolytic herpes simplex virus type 1 (HSV-1) is a promising strategy for cancer treatment. Accumulating evidence indicates that, aside from the extent of replication capability within the tumor, the efficacy of an oncolytic HSV-1 depends on the extent of induction of host antitumor immune responses. Ways to modify the host immune responses toward viral oncolysis include expression of immunostimulatory molecules using oncolytic HSV-1 as a vector and co-administration of reagents that modulate immune reactions. Viral propagation may be enhanced via temporary suppression of innate immune responses. Elucidation of the role of the host immune system in oncolytic HSV-1 therapy is the key to establishing the approach as a useful clinical means for cancer treatment.
Export Options
About this article
Cite this article as:
Fukuhara Hiroshi and Todo Tomoki, Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058907
DOI https://dx.doi.org/10.2174/156800907780058907 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Immuno-Isolation in Oncology - A Mini-Review
Current Pharmaceutical Biotechnology Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Perspective of MiRNAs in Clinical Glioblastoma Research
Current Signal Transduction Therapy Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets Structural Features of the Interleukin-10 Family of Cytokines
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Approaches for the Treatment of Glioblastoma)
Current Cancer Drug Targets Thioethers: An Overview
Current Drug Targets Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry A Review on Medical Image Registration as an Optimization Problem
Current Medical Imaging Applications of Important Polysaccharides in Drug Delivery
Current Pharmaceutical Design